Skip to main content

Table 2 Treatment duration of Abiraterone Acetate

From: Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France

Months N %
≤ 3 85 27.8
]3-6] 84 27.4
>6 127 41.5
Ongoing treatment 10 3.3